Zobrazeno 1 - 1
of 1
pro vyhledávání: '"E S Muehlhofer"'
Autor:
M Szarek, E S Debus, M R Nehler, S S Anand, M R Patel, L P Haskell, E S Muehlhofer, S D Berkowitz, R M Bauersachs, M P Bonaca
Publikováno v:
European Heart Journal. 43
Background In the VOYAGER PAD trial, rivaroxaban reduced first and total (first and subsequent) occurrences of major adverse limb and cardiovascular events in patients with peripheral artery disease (PAD) after lower extremity revascularization (LER)